123

M. Policlinico Ferroviario Central-CC 69- Suc 24-(1424) Buenos Aires,Argentina.

15/16 evaluable patients (pts) with re- lapsed or metastatic NSCLC, 12 male and 3 female; ages between 49 and 71 years, me- dian 619Years , were treated with2VM 26 60 mg/m" on day i-~; DXR 40 mg/m iv on day 1 and BCNU 60 mg/m iv on day 3 as a second line therapy. Cycles were repeated every 4 weeks. 12 pts has metastatic disease and 3 pts locally advanced disease. (liver 2; node 4; bone 4; pleural i; lung i). All pts were previously treated with chemo- therapy other than agents included in this trial. For evaluation purposes, pts recei- ved 2 cycles at least.

Response were as follows: CR 0; PR 4; NC 5; PD 6. One patient was not evaluable for response (early death). Overall respon- se rate was 4/15 pts (26%). Mild to mode- rate bone marrow toxicity was seen. Hair loss, headache and nausea were common side effects. Median survival was 5 months (range 2-10 months).

We conclude that VM 26, DXR and BCNU is an active regimen in NSCLC with accep- table toxicity and warrants further explo- ration.

Phase II Evaluation of Combination of bdto- mycin, Cis-platin~n and S-FU in Adenocar-

cinoma of the Lung. Katakkar, S.B. 2001 W. Orange Grove ~ 408 Tucson, AZ 85704, U.S.A.

Cis-platinum and mitomycin have shown proven efficacy in non-small cell carcino- ma of the lung. Cis-platinum and 5FU in com- bination have shown efficacy in head and neck carcinomas. Hence, combination of all three drugs has been used in non-small cell car- cinoma of the lung to see whether there would be any efficacy.

Five patients with intrathoracic advan- ced poorly differentiated adenocarcinomas of the lung have beeg treated with:

Mitomycin 7.5 mg/m- ~v q 6 weeks Cis-platinum?60 mg/m- iv q 3 weeks 5FU 650 mg/m- iv q 3 weeks. Two out of five patients have achieved

CR which is consolidated with radiation therapy, with an average survival of 7

months. The remaining three patients have achie-

ved 50% or more reduction in the size of the primary or metastatic lesions.

Significant leucopenia was seen in one patient and excessive nausea and vomiting

in another. This study is ongoing and appears to

have a definite impact on adenocarcinoma of the lung although it needs to be evalu- ated further.

Non Small Cell Lung Cancer (NSCLC) Chemo-

therapy (CT): A Five Year's Experience.

De Marinis, F., Maccone, C., Pallotta, G. Pneu-

mological Hospital "C. Forlanini"-3rd Div. 00149 Rome, Italy.

We have revised our cases of NSCLC inoperab- le treated in the past five years with various regimens of CT, doing an evaluation of the response and of a median survival.

Regimen no. pts Rasp. % Survival (CR+PR+MR) (weeks)

CTX-VCR-MTX 40 3 36 ADM-CTX-VCR-H2N 20 1 34 CTX-MTX-CCNU 30 5 26 MTX-ADM-CTX-CCNU 30 4.5 28 CTX-VP 16 40 3.8 28 CDDP(LD)-VP 16 30 26.5 30 CDDP(HD)-VP 16 i0 30.0 28

The analysis of results shows that no always the response is important for the survival, par- ticularly with regimens with "traditional" drugs. With "new" drugs, instead, the median survival of responders is greater than the me- dian of all pts: with the regimen CDDP (LD)- VP 16, the median of all pts was 30 wks, that of responders was 68 wks (144+, 156+). However, the goal of CT for NSCLC stage III (M0-M.) in- operable must be to select the pts to ob%ain more responses for a longer survival, with a comparison with "no therapy-control groups".

Pilot Study of Continuous 5 Fluoro-Uracile (5 FU) Chemotherapy with Cisplatin (DDP) and Bleom[cin (BLM) in ~pidermoid L~ng Cancer (E.L.C.~ Zab~e-, CI., Khaya~-, D., Gouva-, S., Jacquil- lat-, CI., Clavier , J. i. Department of Pneu- mology CHRU Brest (29200) ans. 2. Department of Oncology CHRU Piti~ Salp~tri~re Paris 75013, France.

From January, to December 1984, we treated 18 consecutive patients with ELC (mean age ~ 60) with a combination of 3 drugs: DDP~ 20 mg/m / day, BLM: 5 mg/m~/day, 5 FU: 1 g/m /day in con- tinuous infusion. DDP and BLM were given for 5 days and 5 FU for 4 days, courses repeated every 21 days.

Among the 18 patients (5 stage i, 2 st. 2, 5 st. 3, 6 st. 4 UICCTNM) 17 are evaluable and received chemotherapy for 2 months (3 patients) or 3 months (14 patients) before evaluation. Then 8 patients underwent curative surgery and two more courses of chemotherapy (4stl-2st2-2st 3); 9 patients received mediastinal irradiati- on (istl, 3st3, 6st4) even after other drug combinations in 7 patients.

Results show a response rate of 47% with differences according to the staging (stl+2: 71%, st3 : 40%, st4: 20%). Among the responders (R), were noted 3 complete responses (2stl, ist3) confirmed by thoracotomy, and 5 partial respon- ses. Non-responders (NR) were 8 stabilisations and 1 progression (st 3).

Toxicity was mild as shown in the following table.